BioNexus Gene Lab Corp
For the period ended Dec 31, 2025. Filed Apr 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 3. Legal Proceedings
From time to time, the Company may be involved in claims, disputes, investigations, or legal proceedings arising in the ordinary course of business.
As previously disclosed, the Company has been reviewing certain historical transactions involving former officers of Chemrex Corporation Sdn. Bhd. and related governance and approval matters. That review remains ongoing, and the Company is continuing to assess whether any claims or legal actions should be pursued in connection with those matters.
As of the date of this Annual Report, except for the foregoing review and related matters, the Company is not a party to any material legal proceeding, and, to the Company’s knowledge, no material legal proceeding is pending or threatened against the Company or its subsidiaries that the Company believes would have a material adverse effect on its business, financial condition, or results of operations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.